Small Molecules
24 October 2014
Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer23 October 2014
Santen Announces Positive Outcome of the European Decentralized Procedure for Approval of TAPTIQOM22 October 2014
Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor22 October 2014
Relypsa Submits New Drug Application to U.S. FDA Seeking Approval for Patiromer for Oral Suspension to Treat Hyperkalemia22 October 2014
Alkermes’ New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA22 October 2014
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin’s or T-Cell Non-Hodgkin’s Lymphoma22 October 2014
Phosplatin Therapeutics Announces First Patients Enrolled in Phase I First-in-Human Clinical Trial in Solid Tumors22 October 2014
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate21 October 2014
ChemoCentryx’s Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective in CCR9 Blockade in Phase I Study21 October 2014
Omeros Provides Update on PDE10 Inhibitor Program21 October 2014
Ivantis Announces HYDRUS II Glaucoma Study Met Primary Endpoint In a Randomized Controlled Trial at Two Years20 October 2014
ChemoCentryx Releases Phase III SHIELD 4 Clinical Results in Patients With Crohn’s Disease20 October 2014
Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy20 October 2014
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom’s macroglobulinemia20 October 2014
Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting20 October 2014
Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 01120 October 2014
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG WeekNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports